SAN DIEGO (AP) — SAN DIEGO (AP) — Regulus Therapeutics Inc. (RGLS) on Tuesday reported a loss of $7 million in its second quarter.
On a per-share basis, the San Diego-based company said it had a loss of 37 cents.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RGLS at https://www.zacks.com/ap/RGLS
Donald Trump’s aides have drawn up secret plans to oust the chairman of the Federal Reserve and allow the president to set interest rates, according to reports.
Walmart's CEO went from earning $6.50 an hour to $25 million a year—here are his three tips for climbing the corporate ladder like him
These proven wealth builders could be exactly what you're searching for right now.
The property report includes 85 major metropolitan areas in the U.S. with populations of at least 750,000.
Here's what could happen next to Microsoft shares.
It's been an "everything buy bonds" bull rally in markets for months, but BofA is cautiously watching a couple of indicators.
Opportunistic investors can still find bargains, even with the Nasdaq Composite up 49% since the start of 2023.
Nvidia and Super Micro Computer have been the best-performing S&P 500 stocks of 2024, but select Wall Street analysts still see substantial upside for shareholders.
Baron, whose largest position is in Tesla, is betting the new shift in strategy for Tesla’s low-cost car will fill its increasingly empty factories.
Jamie Dimon and Jerome Powell are taking the European viewpoint on soaring debt levels in the U.S.